Sale

Epilepsy Drugs Market

Epilepsy Drugs Market Size, Share, Trends, Growth, Report: By Seizure Type: Focal Seizures, Generalized Seizures, Non-epileptic Seizures, Others; By Drug Generation: First Generation Drugs, Second Generation Drugs, Others; By Age Group; By Route of Administration; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Epilepsy Drugs Market Size

The epilepsy drugs market was valued at USD 8193.5 million in 2023, driven by the rising prevalence of epilepsy and neurological disorders across the 8 major markets. The market is expected to grow at a CAGR of 4.40% during the forecast period of 2024-2032, with the values likely to attain USD 12025.78 million by 2032.

 

Epilepsy Drugs Market Outlook

  • In October 2023 a study revealed XEN1101's efficacy in reducing seizures by over 50%, offering a swift, safe, and effective treatment for focal epilepsy, potentially reshaping the landscape of epilepsy drug therapy globally.
  • In January 2024, Eisai Co., Ltd. for Fycompa® injection was approved in Japan, offering a solution for temporary inability to administer oral medication, ensuring uninterrupted epilepsy treatment.
  • The epilepsy drugs market is expected to be driven by technological advancements in diagnostic tools and treatment modalities, such as neuroimaging techniques and neuromodulation devices contributing to the market expansion.

 

Epilepsy Drugs Market Overview

Epilepsy is a neurological disorder characterised by recurrent seizures, affecting millions globally. The epilepsy drugs market is driven by the increasing prevalence of epilepsy, due to which the need for the development of innovative antiepileptic drugs (AEDs) by pharmaceutical companies has heightened. The market is fuelled by the escalating advancements in personalised medicine and diagnostic technologies. The rising efforts to increase awareness among people about the available treatments are also contributing to the market growth. With expanding healthcare infrastructure in developing regions, the epilepsy drugs market is poised for substantial growth.

 

Epilepsy Drugs Market Growth Factors

Regulatory Approvals Marking Significant Milestones in Epilepsy Treatment

In January 2024, the Japanese Ministry of Health, Labour and Welfare approved Fycompa® (perampanel), the injection form of an antiepileptic drug (AED) in Japan. The drug is an internally developed product of Eisai Co., Ltd and has been approved particularly as an alternative during situations when oral administration is temporarily impossible. Fycompa, an innovative AED discovered at Eisai’s Tsukuba Research Laboratories. It acts as a highly selective, noncompetitive AMPA receptor antagonist, aiming to mitigate neuronal hyper-excitation associated with seizures by modulating glutamate activity.

 

This injection offers continuity in epilepsy patients by addressing concerns of interrupted treatment during situations like surgeries. Being the sole AMPA receptor antagonist-based AED, this expansion of Fycompa’s administration route facilitates patients who are unable to use oral medication temporarily. The major focus of Eisai Co., Ltd has always been neurology, and epilepsy in particular. This development aligns with the company’s vision to enhance the quality of life for epilepsy patients. Such innovative drug developments and expanded treatment options are poised to drive the market growth, meeting the diverse needs of patients worldwide and potentially driving market expansion in the forecast period.

 

Surge in Drug Development Initiatives to Meet Rising the Epilepsy Drugs Market Demand

In October 2023, a groundbreaking study discovered the efficacy of an investigational medication, XEN1101, in significantly reducing seizure frequency. The medication demonstrated a reduction of more than 50 percent in some patients and even eliminated seizures overall in some patients, which is a significant advancement in epilepsy treatment. The positive findings from the phase 2b clinical trial conducted at NYU Grossman School of Medicine underscore XEN1101's potential as a swift, safe, and effective adjunctive therapy for focal epilepsy.

 

As XEN1101 offers a novel mechanism of action as a potassium-channel opener, it represents a significant breakthrough in epilepsy drug development. These promising results are poised to drive substantial growth in the market as patients and healthcare providers increasingly embrace this innovative treatment option. Such advancements also contribute to expanding pharmaceutical companies' market opportunities and fostering advancements in epilepsy care worldwide, fuelling the market growth.

 

Epilepsy Drugs Market Trends

Key Trends Impact
Increasing Prevalence of the Condition The rising prevalence of neurological disorders including epilepsy is contributing to the growth of the global epilepsy drug market.
Advancement in Drug Development  Pharmaceutical companies continue to invest in research and development in order to introduce new and improved antiepileptic drugs (AEDs). Such advancements are poised to boost market growth. These drugs aim to provide better efficacy, fewer side effects, and improved patient compliance compared to traditional treatments.
Demand for Generic Drugs The significant presence of generic drugs and latest patent expirations drive the market growth. Patent expirations of several blockbuster AEDs have led to the entry of generic versions, driving competition and increased cost-effectiveness.
Rising Awareness Around the Condition Increasing efforts to raise awareness about epilepsy and reduce the stigma associated with the condition are encouraging more individuals to seek diagnosis and treatment. This heightened awareness contributes to market growth.

 

Epilepsy Drugs Market Segmentation 

Market Breakup by Seizure Type
 

  • Focal Seizures
  • Generalized Seizures
  • Non-epileptic Seizures
  • Others

 

Market Breakup by Drug Generation

  • First Generation Drugs
  • Second Generation Drugs
  • Third Generation Drugs

 

Market Breakup by Age Group

  • Pediatric
  • Geriatric
  • Adult

 

Market Breakup by Route of Administration

  • Oral
  • Nasal
  • Injectable
  • Others

 

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

 

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan
  • India

 

Epilepsy Drugs Market Share

Focal Seizures Lead Seizure Type Segmentation

Seizure type segmentation includes focal seizures, generalized seizures, non-epileptic seizures, and others. Focal seizures lead the market segment due to their prevalence and distinct characteristics. Focal seizures require targeted treatment approaches, driving pharmaceutical companies to develop specialised medications, tailored to address the unique needs of patients experiencing focal epilepsy.

 

First Generation Dominates the Drug Generation Segmentation

Market share based on drug generation includes first-generation drugs, second-generation drugs, and third-generation drugs. Out of these, first-generation drugs dominate the drug generation segmentation in the global market. This can be attributed to its established efficacy, familiarity among physicians, and lower cost compared to newer generations.

 

Oral Route of Administration Most Preferred

Market segmentation based on the route of administration includes oral, nasal, injectable, and others.  The oral route of administration is most preferred in the global epilepsy drugs market due to its convenience, ease of use, and high patient acceptance. Oral medications offer flexible dosing regimens while providing efficient systemic drug delivery simultaneously, contributing to better seizure management and patient compliance.

 

Epilepsy Drugs Market Analysis by Region

Based on the regional analysis, the market covers United States, EU-4 (Germany, France, Italy, Spain)and the United Kingdom, Japan and India, with each region contributing to the overall dynamics of the market. The United States leads the epilepsy drugs market due to factors such as an increasing prevalence of the condition, presence of advanced healthcare infrastructure, robust research and development activities, and significant investments in innovative drug therapies. Additionally, favorable regulatory policies and strong market competition contribute to the region's dominance in the market.

 

Further, Japan and India are witnessing steady growth due to rising prevalence, improving healthcare infrastructure, increasing awareness, and better access to treatment options. The region is poised to witness a significant growth in the forecast period.

 

Leading Players in the Epilepsy Drugs Market

The key features of the market report include patent analysis, grants analysis, clinical trial analysis, and latest strategic initiatives by the leading players. The major companies in the market are as follows:

 

GlaxoSmithKline Plc

GlaxoSmithKline Plc (GSK) was established in 2000 and is currently headquartered in Brentford, London. It is a prominent pharmaceutical company with a significant market presence. Some of the well-known epilepsy drugs include Lamictal (Lamotrigine), Epanutin (Phenytoin) and Trobalt (Retigabine) among others.

 

Eisai Co., Ltd.

It is a leading pharmaceutical company based out of Japan. This company is dedicated to develop and discover several effective drugs that address the different needs of patients.

 

Novartis AG

It is a Swiss multinational pharmaceutical company based out of Switzerland and known for its elaborate portfolio of epilepsy drugs. Tegretol (Carbamazepine), Trileptal (Oxcarbazepine) and Sabril (Vigabatrin) are some of the examples.

 

Other companies in the market include UCB Pharma S.A, Sanofi, S K Biopharmaceuticals, Novel Laboratories Inc., Pfizer Inc., Neurelis, Inc., Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Sumitomo Pharma, Jazz Pharmaceuticals, Inc., Sun Pharmaceuticals Industries Ltd. and Alkem Laboratories Ltd.

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Seizure Type
  • Drug Generation 
  • Age Group
  • Route of Administration
  • Distribution Channel 
  • Region
Breakup by Seizure Type
  • Focal Seizures
  • Generalized Seizures
  • Non-epileptic Seizures
  • Others
Breakup by Drug Generation
  • First Generation Drugs
  • Second Generation Drugs
  • Third Generation Drugs
Breakup by Age Group
  • Pediatric
  • Geriatric
  • Adult
Breakup by Route of Administration
  • Oral
  • Nasal
  • Injectable 
  • Others
Breakup by Distribution Channel 
  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • UCB Pharma S.A 
  • GlaxoSmithKline Plc 
  • Sanofi
  • S K Biopharmaceuticals
  • Eisai Co., Ltd.
  • Novartis AG
  • Novel Laboratories Inc.
  • Pfizer Inc.
  • Neurelis, Inc.
  • Dr. Reddy’s Laboratories
  • Sumitomo Pharma 
  • Jazz Pharmaceuticals, Inc.
  • Sun Pharmaceuticals Industries Ltd.
  • Alkem Laboratories Ltd 

 

Key Queries Solved in the Epilepsy Drugs Market Report

  • What was the epilepsy drugs market value in 2023?  
  • What is the epilepsy drugs market forecast outlook for 2024-2032?  
  • What are the major factors aiding the market demand?  
  • What are the major market trends? 
  • What is the market segmentation based on the seizure type?
  • What is the market breakup by drug generation?
  • How is the market segmented based on the route of administration?
  • What are segments based on distribution channels?
  • Which age group does this drug serve?
  • What are the major markets according to the EMR report? 
  • Who are the key players in the epilepsy drugs market?
  • How will the market landscape evolve in the upcoming years? 
  • What are the major drivers, opportunities, and restraints in the market? 
  • What will be the effect of each driver, challenge, and opportunity on the market? 
  • Which country is poised to lead the market share in the forecast period? 
  • Which segment has the highest impact on the market size? 
  • What is the patent landscape of the market?
  • What drugs are currently under clinical trials?
  • How are partnerships, collaborations, mergers and acquisitions shaping the market dynamics?

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3     Epilepsy Drugs Market Overview: 8 Major Market 

    3.1     Epilepsy Drugs Market Historical Value (2017-2023) 
    3.2     Epilepsy Drugs Market Forecast Value (2024-2032)
4    Vendor Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors 
5    Epilepsy: Disease Overview 
    5.1    Guidelines and Stages
    5.2    Pathophysiology
    5.3    Screening and Diagnosis
    5.4    Therapy Pathway
6    Patient Profile
    6.1    Patient Profile Overview
    6.2    Patient Psychology and Emotional Impact Factors
    6.3    Risk Assessment and Therapy Success Rate
7    Epilepsy Epidemiology Scenario and Forecast – 8 Major Markets
    7.1    8MM Epidemiology Scenario Overview (2017-2032)
        7.1.1    Prevalence, by Country
            7.1.1.1    U.S.
            7.1.1.2    U.K.
            7.1.1.3    EU4
            7.1.1.4    India 
            7.1.1.5    Japan
        7.1.2    Mortality, by Country
            7.1.2.1    U.S.
            7.1.2.2    U.K.
            7.1.2.3    EU4
            7.1.2.4    India 
            7.1.2.5    Japan
        7.1.3    Treatment Seeking Rate, by Country
            7.1.3.1    U.S.
            7.1.3.2    U.K.
            7.1.3.3    EU4
            7.1.3.4    India 
            7.1.3.5    Japan
8    Epilepsy Drugs Market Landscape: 8 Major Market*
    8.1     Epilepsy Drugs Market: Developers Landscape
        8.1.1    Analysis by Year of Establishment
        8.1.2    Analysis by Company Size
        8.1.3    Analysis by Region
    8.2     Epilepsy Drugs Market: Product Landscape
        8.2.1    Analysis by Seizure Type
        8.2.2    Analysis by Drug Generation
9    Epilepsy Market Therapy Challenges and Unmet Needs
    9.1    Therapy Pathway Challenges
    9.2    Compliance and Drop-Out Analysis
    9.3    Awareness and Prevention Gaps
10    Cost of Therapy
11     Epilepsy Drugs Market Dynamics

    11.1     Market Drivers and Constraints
    11.2     SWOT Analysis
        11.2.1    Strengths
        11.2.2    Weaknesses
        11.2.3    Opportunities
        11.2.4    Threats
    11.3     PESTEL Analysis 
        11.3.1    Political 
        11.3.2    Economic 
        11.3.3    Social 
        11.3.4    Technological 
        11.3.5    Legal 
        11.3.6    Environment
    11.4     Porter’s Five Forces Model
        11.4.1    Bargaining Power of Suppliers
        11.4.2    Bargaining Power of Buyers
        11.4.3    Threat of New Entrants
        11.4.4    Threat of Substitutes
        11.4.5    Degree of Rivalry
    11.5     Key Demand Indicators 
    11.6    Key Price Indicators
    11.7    Industry Events, Initiatives, and Trends 
    11.8    Value Chain Analysis
12     Epilepsy Drugs Market Segmentation (2017-2032): 8 Major Market
    12.1     Epilepsy Drugs Market (2017-2032) by Seizure Type
        12.1.1    Market Overview
        12.1.2    Focal Seizures
        12.1.3    Generalized Seizures
        12.1.4    Non-epileptic Seizures
        12.1.5    Others
    12.2     Epilepsy Drugs Market (2017-2032) by Drug Generation 
        12.2.1    Market Overview
        12.2.2    First Generation Drugs
        12.2.3    Second Generation Drugs
        12.2.4    Third Generation Drugs
    12.3     Epilepsy Drugs Market (2017-2032) by Age Group
        12.3.1    Market Overview
        12.3.2    Pediatric
        12.3.3    Geriatric
        12.3.4    Adult
    12.4     Epilepsy Drugs Market (2017-2032) by Route of Administration
        12.4.1    Market Overview
        12.4.2    Oral
        12.4.3    Nasal
        12.4.4    Injectable 
        12.4.5    Others
    12.5     Epilepsy Drugs Market (2017-2032) by Distribution Channel 
        12.5.1    Market Overview
        12.5.2    Hospital Pharmacies
        12.5.3    Drug Stores and Retail Pharmacies
        12.5.4    Online Providers
    12.6     Epilepsy Drugs Market (2017-2032) by Region
        12.6.1    Market Overview
        12.6.2    United States
        12.6.3    EU-4 and the United Kingdom
            12.6.3.1    Germany
            12.6.3.2    France
            12.6.3.3    Italy
            12.6.3.4    Spain
            12.6.3.5    United Kingdom
        12.6.4    Japan
        12.6.5    India
13    United States Epilepsy Drugs Market (2017-2032)
    13.1     United States Epilepsy Drugs Market Historical Value (2017-2023) 
    13.2     United States Epilepsy Drugs Market Forecast Value (2024-2032)
    13.3     United States Epilepsy Drugs Market (2017-2032) by Seizure Type
        13.3.1    Market Overview
        13.3.2    Focal Seizures
        13.3.3    Generalized Seizures
        13.3.4    Non-epileptic Seizures
        13.3.5    Others
    13.4      United States Epilepsy Drugs Market (2017-2032) by Drug Generation 
        13.4.1    Market Overview
        13.4.2    First Generation Drugs
        13.4.3    Second Generation Drugs
        13.4.4    Third Generation Drugs
    13.5      United States Epilepsy Drugs Market (2017-2032) by Age Group
        13.5.1    Market Overview
        13.5.2    Pediatric
        13.5.3    Geriatric
        13.5.4    Adult
    13.6      United States Epilepsy Drugs Market (2017-2032) by Route of Administration
        13.6.1    Market Overview
        13.6.2    Oral
        13.6.3    Nasal
        13.6.4    Others
    13.7      United States Epilepsy Drugs Market (2017-2032) by Distribution Channel 
        13.7.1    Market Overview
        13.7.2    Hospital Pharmacies
        13.7.3    Drug Stores and Retail Pharmacies
        13.7.4    Online Providers
14    EU-4 and United Kingdom Epilepsy Drugs Market (2017-2032)
    14.1    EU-4 and United Kingdom Epilepsy Drugs Market Historical Value (2017-2023)
    14.2    EU-4 and United Kingdom Epilepsy Drugs Market Forecast Value (2024-2032)
    14.3     EU-4 and United Kingdom Epilepsy Drugs Market (2017-2032) by Seizure Type
        14.3.1    Market Overview
        14.3.2    Focal Seizures
        14.3.3    Generalized Seizures
        14.3.4    Non-epileptic Seizures
        14.3.5    Others
    14.4     EU-4 and United Kingdom Epilepsy Drugs Market (2017-2032) by Drug Generation 
        14.4.1    Market Overview
        14.4.2    First Generation Drugs
        14.4.3    Second Generation Drugs
        14.4.4    Third Generation Drugs
    14.5     EU-4 and United Kingdom Epilepsy Drugs Market (2017-2032) by Age Group
        14.5.1    Market Overview
        14.5.2    Pediatric
        14.5.3    Geriatric
        14.5.4    Adult
    14.6     EU-4 and United Kingdom Epilepsy Drugs Market (2017-2032) by Route of Administration
        14.6.1    Market Overview
        14.6.2    Oral
        14.6.3    Nasal
        14.6.4    Injectable 
        14.6.5    Others
    14.7     EU-4 and United Kingdom Epilepsy Drugs Market (2017-2032) by Distribution Channel 
        14.7.1    Market Overview
        14.7.2    Hospital Pharmacies
        14.7.3    Drug Stores and Retail Pharmacies
        14.7.4    Online Providers
15    Japan Epilepsy Drugs Market
    15.1    Japan Epilepsy Drugs Market Historical Value (2017-2023) 
    15.2    Japan Epilepsy Drugs Market Forecast Value (2024-2032)
    15.3    Japan Epilepsy Drugs Market (2017-2032) by Seizure Type
        15.3.1    Market Overview
        15.3.2    Focal Seizures
        15.3.3    Generalized Seizures
        15.3.4    Non-epileptic Seizures
        15.3.5    Others
    15.4     Japan Epilepsy Drugs Market (2017-2032) by Drug Generation 
        15.4.1    Market Overview
        15.4.2    First Generation Drugs
        15.4.3    Second Generation Drugs
        15.4.4    Third Generation Drugs
    15.5     Japan Epilepsy Drugs Market (2017-2032) by Age Group
        15.5.1    Market Overview
        15.5.2    Pediatric
        15.5.3    Geriatric
        15.5.4    Adult
    15.6    Japan Epilepsy Drugs Market (2017-2032) by Route of Administration
        15.6.1    Market Overview
        15.6.2    Oral
        15.6.3    Nasal
        15.6.4    Injectable 
        15.6.5    Others
    15.7     Japan Epilepsy Drugs Market (2017-2032) by Distribution Channel 
        15.7.1    Market Overview
        15.7.2    Hospital Pharmacies
        15.7.3    Drug Stores and Retail Pharmacies
        15.7.4    Online Providers
16    India Epilepsy Drugs Market
    16.1    India Epilepsy Drugs Market (2017-2032) Historical Value (2017-2023) 
    16.2    India Epilepsy Drugs Market (2017-2032) Forecast Value (2024-2032)
    16.3    India Epilepsy Drugs Market (2017-2032) by Seizure Type
        16.3.1    Market Overview
        16.3.2    Focal Seizures
        16.3.3    Generalized Seizures
        16.3.4    Non-epileptic Seizures
        16.3.5    Others
    16.4    India Epilepsy Drugs Market (2017-2032) by Drug Generation 
        16.4.1    Market Overview
        16.4.2    First Generation Drugs
        16.4.3    Second Generation Drugs
        16.4.4    Third Generation Drugs
    16.5    India Epilepsy Drugs Market (2017-2032) by Age Group
        16.5.1    Market Overview
        16.5.2    Pediatric
        16.5.3    Geriatric
        16.5.4    Adult
    16.6    India Epilepsy Drugs Market (2017-2032) by Route of Administration
        16.6.1    Market Overview
        16.6.2    Oral
        16.6.3    Nasal
        16.6.4    Injectable 
        16.6.5    Others
    16.7    India Epilepsy Drugs Market (2017-2032) by Distribution Channel 
        16.7.1    Market Overview
        16.7.2    Hospital Pharmacies
        16.7.3    Drug Stores and Retail Pharmacies
        16.7.4    Online Providers
17    Regulatory Framework
    17.1     Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1     Analysis by Type of Patent
    18.2     Analysis by Publication Year
    18.3     Analysis by Issuing Authority
    18.4     Analysis by Patent Age
    18.5     Analysis by CPC Analysis
    18.6     Analysis by Patent Valuation 
    18.7     Analysis by Key Players
19    Clinical Trial Analysis
    19.1    Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Grants Analysis
    20.1     Analysis by Year
    20.2     Analysis by Amount Awarded
    20.3     Analysis by Issuing Authority
    20.4     Analysis by Grant Application
    20.5     Analysis by Funding Institute
    20.6     Analysis by Departments
    20.7     Analysis by Recipient Organization 
21    Strategic Analysis
    21.1     Analysis by Partnership Instances
    21.2     Analysis by Type of Partnership
    21.3     Analysis by Leading Players
    21.4     Analysis by Geography
22    Supplier Landscape
    22.1    Market Share by Top 5 Companies  
    22.2      UCB Pharma S.A 
        22.2.1    Financial Analysis
        22.2.2    Product Portfolio
        22.2.3    Demographic Reach and Achievements
        22.2.4    Mergers and Acquisitions
        22.2.5    Certifications 
    22.3    GlaxoSmithKline Plc 
        22.3.1    Financial Analysis
        22.3.2    Product Portfolio
        22.3.3    Demographic Reach and Achievements
        22.3.4    Mergers and Acquisitions
        22.3.5    Certifications
    22.4    Sanofi 
        22.4.1    Financial Analysis
        22.4.2    Product Portfolio
        22.4.3    Demographic Reach and Achievements
        22.4.4    Mergers and Acquisitions
        22.4.5    Certifications
    22.5    S K Biopharmaceuticals     
        22.5.1    Financial Analysis
        22.5.2    Product Portfolio
        22.5.3    Demographic Reach and Achievements
        22.5.4    Mergers and Acquisitions
        22.5.5    Certifications
    22.6    Eisai Co., Ltd .
        22.6.1    Financial Analysis
        22.6.2    Product Portfolio
        22.6.3    Demographic Reach and Achievements
        22.6.4    Mergers and Acquisitions
        22.6.5    Certifications
    22.7    Novartis AG 
        22.7.1    Financial Analysis
        22.7.2    Product Portfolio
        22.7.3    Demographic Reach and Achievements
        22.7.4    Mergers and Acquisitions
        22.7.5    Certifications
    22.8    Novel Laboratories Inc .
        22.8.1    Financial Analysis
        22.8.2    Product Portfolio
        22.8.3    Demographic Reach and Achievements
        22.8.4    Mergers and Acquisitions
        22.8.5    Certifications
    22.9    Pfizer Inc .
        22.9.1    Financial Analysis
        22.9.2    Product Portfolio
        22.9.3    Demographic Reach and Achievements
        22.9.4    Mergers and Acquisitions
        22.9.5    Certifications
    22.10    Neurelis, Inc .
        22.10.1    Financial Analysis
        22.10.2    Product Portfolio
        22.10.3    Demographic
        22.10.4    Mergers and Acquisitions
        22.10.5    Certifications
    22.11    Dr. Reddy’s Laboratories 
        22.11.1    Financial Analysis
        22.11.2    Product Portfolio
        22.11.3    Demographic Reach and Achievements
        22.11.4    Mergers and Acquisitions
        22.11.5    Certifications 
    22.12    Sumitomo Pharma 
        22.12.1    Financial Analysis
        22.12.2    Product Portfolio
        22.12.3    Demographic Reach and Achievements
        22.12.4    Mergers and Acquisitions
        22.12.5    Certifications  
    22.13    Jazz Pharmaceuticals, Inc .
        22.13.1    Financial Analysis
        22.13.2    Product Portfolio
        22.13.3    Demographic Reach and Achievements
        22.13.4    Mergers and Acquisitions
        22.13.5    Certifications 
    22.14    Sun Pharmaceuticals Industries Ltd .
        22.14.1    Financial Analysis
        22.14.2    Product Portfolio
        22.14.3    Demographic Reach and Achievements
        22.14.4    Mergers and Acquisitions
        22.14.5    Certifications 
    22.15    Alkem Laboratories Ltd 
        22.15.1    Financial Analysis
        22.15.2    Product Portfolio
        22.15.3    Demographic Reach and Achievements
        22.15.4    Mergers and Acquisitions
        22.15.5    Certifications 
23     Epilepsy Drugs Market – Distribution Model (Additional Insight)
    23.1     Overview 
    23.2     Potential Distributors 
    23.3     Key Parameters for Distribution Partner Assessment 
24    Key Opinion Leaders (KOL) Insights (Additional Insight)
25    Payment Methods (Additional Insight)

    25.1     Government Funded
    25.2     Private Insurance
    25.3     Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

 

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

 

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER